|
1 Indications And Usage Ixempra (Ixabepilone) Is Indicated In Combination With Capecitabine For The Treatment Of Patients With Metastatic Or Locally Advanced Breast Cancer Resistant To Treatment With An Anthracycline And A Taxane, Or Whose Cancer Is Taxane Resistant And For Whom Further Anthracycline Therapy Is Contraindicated. Anthracycline Resistance Is Defined As Progression While On Therapy Or Within 6 Months In The Adjuvant Setting Or 3 Months In The Metastatic Setting. Taxane Resistance Is Defined As Progression While On Therapy Or Within 12 Months In The Adjuvant Setting Or 4 Months In The Metastatic Setting. Ixempra Is Indicated As Monotherapy For The Treatment Of Metastatic Or Locally Advanced Breast Cancer In Patients Whose Tumors Are Resistant Or Refractory To Anthracyclines, Taxanes, And Capecitabine. Ixempra, A Microtubule Inhibitor, In Combination With Capecitabine Is Indicated For The Treatment Of Metastatic Or Locally Advanced Breast Cancer In Patients After Failure Of An Anthracycline And A Taxane ( 1 ). Ixempra As Monotherapy Is Indicated For The Treatment Of Metastatic Or Locally Advanced Breast Cancer In Patients After Failure Of An Anthracycline, A Taxane, And Capecitabine ( 1 ).
|